Seminars in Oncology
Volume 30, Issue 5 , Pages 659-666 , October 2003

DNA vaccines: an active immunization strategy for prostate cancer

  • Jedd D Wolchok

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jedd D. Wolchok, MD, PhD, Clinical Immunology and Genitourinary Oncology Services, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    • Clinical Immunology and Genitourinary Oncology Services, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Polly D Gregor

      Affiliations

    • Clinical Immunology and Genitourinary Oncology Services, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Luke T Nordquist

      Affiliations

    • Clinical Immunology and Genitourinary Oncology Services, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Susan F Slovin

      Affiliations

    • Clinical Immunology and Genitourinary Oncology Services, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Howard I Scher

      Affiliations

    • Clinical Immunology and Genitourinary Oncology Services, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

References 

  1. Shankaran V, Ikeda H, Bruce AT, et al.  IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–1111
  2. Livingston PO, Takeyama H, Pollack MS, et al.  Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int J Cancer. 1983;31:567–575
  3. Gercovich FG, Gutterman JU, Mavligit GM, et al.  Active specific immunization in malignant melanoma. Med Pediatr Oncol. 1975;1:277–287
  4. Slingluff CL, Seigler HF. Immunotherapy for malignant melanoma with a tumor cell vaccine. Ann Plast Surg. 1992;28:104–107
  5. Morton DL, Foshag LJ, Nizze JA, et al.  Active specific immunotherapy in malignant melanoma. Semin Surg Oncol. 1989;5:420–425
  6. Haigh PI, Difronzo LA, Gammon G, et al.  Vaccine therapy for patients with melanoma. Oncology (Huntingt). 1999;13:1561–1574
  7. Chan AD, Morton DL. Active immunotherapy with allogeneic tumor cell vaccines (present status). Semin Oncol. 1998;25:611–622
  8. Bystryn JC, Henn M, Li J, et al.  Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res. 1992;52:5948–5953
  9. Bystryn JC. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens. Ann NY Acad Sci. 1993;690:190–203
  10. Okamoto T, Irie RF, Fujii S, et al.  Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol. 1998;111:1034–1039
  11. Huang SK, Okamoto T, Morton DL, et al.  Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J Invest Dermatol. 1998;111:662–667
  12. Reynolds SR, Celis E, Sette A, et al.  HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol. 1998;161:6970–6976
  13. Eaton JD, Perry MJ, Nicholson S, et al.  Allogeneic whole-cell vaccine (A phase I/II study in men with hormone- refractory prostate cancer). BJU Int. 2002;89:19–26
  14. Berd D, Murphy G, Maguire HC, et al.  Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res. 1991;51:2731–2734
  15. Dranoff G, Jaffee E, Lazenby A, et al.  Vaccination with irradiated tumor cell engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90: 35339–33543
  16. Nelson WG, Simons JW, Mikhak B, et al.  Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol. 2000;46(suppl):S67–S72
  17. Simons JW, Mikhak B, Chang JF, et al.  Induction of immunity to prostate cancer antigens (Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer). Cancer Res. 1999;59:5160–5168
  18. Zhang S, Zhang HS, Reuter VE, et al.  Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res. 1998;4:295–302
  19. Wang ZG, Williams LJ, Zhang XF, et al.  Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine (Isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens). Proc Natl Acad Sci USA. 2000;97:2719–2724
  20. Slovin SF, Scher HI. Peptide and carbohydrate vaccines in relapsed prostate cancer (Immunogenicity of synthetic vaccines in man—Clinical trials at Memorial Sloan-Kettering Cancer Center). Semin Oncol. 1999;26:448–454
  21. Slovin SF, Ragupathi G, Adluri S, et al.  Carbohydrate vaccines in cancer (Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man). Proc Natl Acad Sci USA. 1999;96:5710–5715
  22. Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res. 2002;62:5807–5812
  23. Tjoa BA, Murphy GP. Development of dendritic-cell based prostate cancer vaccine. Immunol Lett. 2000;74:87–93
  24. Murphy GP, Tjoa BA, Simmons SJ, et al.  Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides (A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease). Prostate. 1999;38:73–78
  25. Murphy GP, Tjoa BA, Simmons SJ, et al.  Phase II prostate cancer vaccine trial (Report of a study involving 37 patients with disease recurrence following primary treatment). Prostate. 1999;39:54–59
  26. Tjoa BA, Elgamal AA, Murphy GP. Vaccine therapy for prostate cancer. Urol Clin North Am. 1999;26:365–374
  27. Tjoa BA, Simmons SJ, Elgamal A, et al.  Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate. 1999;40:125–129
  28. Tjoa BA, Simmons SJ, Bowes VA, et al.  Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate. 1998;36:39–44
  29. Heiser A, Coleman D, Dannull J, et al.  Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. 2002;109:409–417
  30. Heiser A, Maurice MA, Yancey DR, et al.  Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol. 2001;166:2953–2960
  31. Nair SK, Heiser A, Boczkowski D, et al.  Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med. 2000;6:1011–1017
  32. Kaplan G, Walsh G, Guido LS, et al.  Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor (Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing). J Exp Med. 1992;175:1717–1728
  33. Nasi ML, Lieberman PH, Busam KJ, et al.  Intradermal injection of granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines Cell Mol Ther. 1999;5:139–144
  34. Jager E, Ringhoffer M, Dienes HP, et al.  Granulocyte-macrophage-colony stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer. 1996;67:54–62
  35. Bowne WB, Wolchok JD, Hawkins WG, et al.  Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines Cell Mol Ther. 1999;5:217–225
  36. Przepiorka D, Srivastava PK. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol Med Today. 1998;4:478–484
  37. Srivastava PK. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods. 1997;12:165–171
  38. Blachere NE, Srivastava PK. Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin Cancer Biol. 1995;6:349–355
  39. Srivastava PK, Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol. 1994;6:728–732
  40. Moroi Y, Mayhew M, Trcka J, et al.  Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci USA. 2000;97:3485–3490
  41. Porgador A, Irvine KR, Iwasaki A, et al.  Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med. 1998;188:1075–1082
  42. Casares S, Inaba K, Brumeanu TD, et al.  Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med. 1997;186:1481–1486
  43. Akbari O, Panjwani N, Garcia S, et al.  DNA vaccination (Transfection and activation of dendritic cells as key events for immunity). J Exp Med. 1999;189:169–178
  44. Klinman DM, Yi AK, Beaucage SL, et al.  CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA. 1996;93:2879–2883
  45. Sato Y, Roman M, Tighe H, et al.  Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 1996;273:352–354
  46. Wang R, Doolan DL, Le TP, et al.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 1998;282:476–480
  47. Boyer JD, Cohen AD, Vogt S, et al.  Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis. 2000;181:476–483
  48. Ugen KE, Nyland SB, Boyer JD, et al.  DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine. 1998;16:1818–1821
  49. Bowne WB, Srinivasan R, Wolchok JD, et al.  Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med. 1999;190:1717–1722
  50. Hawkins WG, Gold JS, Dyall R, et al.  Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery. 2000;128:273–280
  51. Weber LW, Bowne WB, Wolchok JD, et al.  Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest. 1998;102:1258–1264
  52. Coyle JT. The nagging question of the function of N-acetylaspartylglutamate. Neurobiol Dis. 1997;4:231–238
  53. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA. 1996;93:749–753
  54. Pinto JT, Suffoletto BP, Berzin TM, et al.  Prostate-specific membrane antigen (A novel folate hydrolase in human prostatic carcinoma cells). Clin Cancer Res. 1996;2:1445–1451
  55. Chang SS, Gaudin PB, Reuter VE, et al.  Prostate-specific membrane antigen (Much more than a prostate cancer marker). Mol Urol. 1999;3:313–320
  56. Silver DA, Pellicer I, Fair WR, et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–85
  57. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–935
  58. Wright GL, Grob BM, Haley C, et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326–334
  59. Murphy GP, Tjoa BA, Simmons SJ, et al.  Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides (A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease). Prostate. 1999;38:73–78
  60. Mincheff M, Tchakarov S, Zoubak S, et al.  Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer (A phase I/II clinical trial). Eur Urol. 2000;38:208–217
  61. Kaufman HL, Wang W, Manola J, et al.  Prime/boost vaccination using poxviruses expressing PSA in D0 prostate cancer (Preliminary results of ECOG 7897, a randomized phase II clinical trial). Proc Am Soc Clin Oncol. 2002;21:4a; (abstr)

PII: S0093-7754(03)00356-7

doi: 10.1016/S0093-7754(03)00356-7

Seminars in Oncology
Volume 30, Issue 5 , Pages 659-666 , October 2003

Article Tools

* Image Usage & Resolution